AxoGen (AXGN)
(Delayed Data from NSDQ)
$13.16 USD
-0.08 (-0.60%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $13.13 -0.03 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.16 USD
-0.08 (-0.60%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $13.13 -0.03 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BRKR Stock Might Gain From the Newly Launched OptoVolt Module
by Zacks Equity Research
At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.
Here's Why You Should Retain Penumbra Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about PEN's strong growth prospects in the Thrombectomy business. Yet, unfavorable forex impacts are concerning.
Reasons to Retain Chemed Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about CHE's strong growth prospects in the VITAS business. Yet, unfavorable macroeconomic conditions are concerning.
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
by Zacks Equity Research
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.
Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors
by Zacks Equity Research
BRKR acquires Dynamic Biosensors or DBS. DBS's unique products, along with BRKR's SPR portfolio, should help the latter establish a leading biosensors business.
New Animal Health Products, Vaccine Sales Support PAHC Stock
by Zacks Equity Research
Phibro Animal Health is focusing on new developments, incremental registrations and volumes of existing vaccine technologies.
Should You Continue to Hold TMO Stock in Your Portfolio?
by Zacks Equity Research
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Here's Why You Should Hold IART Stock in Your Portfolio Now
by Zacks Equity Research
Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
ACB Stock Likely to Gain From Genome BC-Funded Aroma Research Project
by Zacks Equity Research
Aurora Cannabis' new collaboration on the Genome BC-Funded Project addresses distinct cannabis aromas.
Is it the Right Time to Hold EW Stock in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.
Here's Why You Should Retain BRKR Stock in Your Portfolio Now
by Zacks Equity Research
Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.
HYPR Achieves Positive Swoop System Data for ECMO: Stock to Rise?
by Zacks Equity Research
Hyperfine announces a publication on using the Swoop system for patients on ECMO support. The study showed the safety of using an ultra-low-field portable brain MRI on patients undergoing ECMO.
Here's Why You Should Add BSX Stock to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
by Zacks Equity Research
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
Global Expansion, Strategic Innovations Aid Boston Scientific Stock
by Zacks Equity Research
We are impressed with BSX's recent acquisitions that have added numerous products with immense potential.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
by Zacks Equity Research
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
by Zacks Equity Research
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
by Zacks Equity Research
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
by Zacks Equity Research
BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.
RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions
by Zacks Equity Research
ResMed introduces digital and personalized solutions designed to improve sleep health.
Positive Trial Outcome for PulseSelect PFA Likely to Boost MDT Stock
by Zacks Equity Research
Medtronic presents new clinical data on the PulseSelect PFA System and marks its launch in Japan.